Additionally, some in vitro studies reported that knock-down or inhibition of EIF5A2 enhanced the chemosensitivity of HCC cells to 5-FU/doxorubicin and breast cancer cells and bladder cancer cells to doxorubicin [6–9]. This evidence concerns the gene EIF5A2 and hepatocellular carcinoma.